Amedisys (AMED) Tops Q1 EPS by 12c, Offers FY Guidance

Amedisys (NASDAQ: AMED) reported Q1 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $399.3 million versus the consensus estimate of $395.28 million.

GUIDANCE:

Amedisys sees FY2018 EPS of $2.97-$3.08, versus the consensus of $3.00. Amedisys sees FY2018 revenue of $1.6-1.64 million, versus the consensus of $1.63 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• Robinhood prices $2B convertible notes offering due 2029